Sotrovimab Expanded Access Treatment Protocol (COVID-19)

Sponsor

Vir Biotechnology, Inc. (Industry)

Overall Status

Available

CT.gov ID

NCT05235347

Collaborator

(none)

Locations

Study Details

Study Description

Brief Summary

An expanded access program for sotrovimab administered intravenously to participants with COVID-19 illness who meet current authorized/approved criteria for use of sotrovimab.

Condition or Disease	Intervention/Treatment	Phase
Covid19	Biological: Sotrovimab

Study Design

Study Type:

Expanded Access

Official Title:

Sotrovimab Expanded Access Treatment Protocol

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

Ages Eligible for Study:

12 Years and Older

Sexes Eligible for Study:

All

Inclusion Criteria:

In the opinion of the investigator, meets the current Emergency Use Authorization (EUA) eligibility criteria for sotrovimab

patients currently hospitalized for a non-COVID-19 illness who acquire COVID-19 (nosocomial infection) and otherwise meets all the current EUA eligibility criteria

Exclusion Criteria:

Hospitalized due to COVID-19 (excludes nosocomial infection)
Require oxygen therapy due to COVID-19, OR who require an increase in baseline oxygen flow rate due to COVID-19

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Site	Palo Alto	California	United States	94304
2	Site	Boston	Massachusetts	United States	02114
3	Site	Saint Louis	Missouri	United States	63110
4	Site	Seattle	Washington	United States	98109